Revenue: As of FY2025 Q3, the actual value is USD 2.855 K.EPS: As of FY2025 Q3, the actual value is USD -0.98.EBIT: As of FY2025 Q3, the actual value is USD -1.709 M.<h3>Segment Revenue</h3><ul><li>Product Test Sales: $11,270 for the nine months ended September 30, 2025, compared to $30,378 for the same period in 2024.</li><li>Product Test Sales: $2,855 for the three months ended September 30, 2025, compared to $6,580 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: - $5,032,799 for the nine months ended September 30, 2025, compared to - $6,864,145 for the same period in 2024.</li><li>Net Loss: - $1,714,536 for the three months ended September 30, 2025, compared to - $1,412,566 for the same period in 2024.</li><li>Selling, General and Administrative Expenses: $5,032,126 for the nine months ended September 30, 2025, compared to $6,879,853 for the same period in 2024.</li><li>Selling, General and Administrative Expenses: $1,714,452 for the three months ended September 30, 2025, compared to $1,415,547 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $4,364,984 for the nine months ended September 30, 2025, compared to - $3,600,809 for the same period in 2024.</li><li>Net Cash Used in Investing Activities: - $340,951 for the nine months ended September 30, 2025, compared to - $349,577 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $3,233,666 for the nine months ended September 30, 2025, compared to $4,649,453 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Payroll and Related Costs: $1,312,755 for the nine months ended September 30, 2025, compared to $3,898,268 for the same period in 2024.</li><li>Research and Development Expense: $354,345 for the nine months ended September 30, 2025, compared to $23,367 for the same period in 2024.</li><li>Sales and Marketing Expense: $445,566 for the nine months ended September 30, 2025, compared to $144,240 for the same period in 2024.</li><li>Legal and Professional Fees: $770,060 for the nine months ended September 30, 2025, compared to $590,273 for the same period in 2024.</li><li>Consulting and Contractor Fees: $528,598 for the nine months ended September 30, 2025, compared to $560,113 for the same period in 2024.</li><li>Insurance Expense: $473,153 for the nine months ended September 30, 2025, compared to $547,667 for the same period in 2024.</li><li>Filing Fees: $71,700 for the nine months ended September 30, 2025, compared to $82,212 for the same period in 2024.</li><li>Transfer Agent Fees: $23,250 for the nine months ended September 30, 2025, compared to $35,551 for the same period in 2024.</li><li>Software and Web Computing Expenses: $251,055 for the nine months ended September 30, 2025, compared to $217,205 for the same period in 2024.</li><li>Board Compensation: $149,152 for the nine months ended September 30, 2025, compared to $149,910 for the same period in 2024.</li><li>Investor Relations Expense: $8,948 for the nine months ended September 30, 2025, compared to $76,453 for the same period in 2024.</li><li>General Corporate Overhead Expenses: $360,881 for the nine months ended September 30, 2025, compared to $368,238 for the same period in 2024.</li><li>Amortization Expense: $59,578 for the nine months ended September 30, 2025, compared to $14,389 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Cardio Diagnostics Holdings, Inc. plans to develop additional products, including clinical tests for stroke, congestive heart failure, and diabetes. The company also aims to offer laboratory services once their laboratory setup is complete, expand their clinical and health economics evidence portfolio, leverage their CPT PLA codes, and expand reimbursement efforts.</li><li>Non-Core Business: The company is exploring additional market opportunities in the US and internationally, scaling internal operations capabilities to improve efficiency and reduce cost of goods sold, and pursuing potential strategic partnerships and acquisitions of synergistic companies.</li><li>Priority: Emphasis is placed on expanding the adoption of their products across key channels, including health systems and self-insured employers, and exploring additional market opportunities in the US and internationally.</li></ul>

CARDIO DIAGNOSTICS HOLDINGS INC C/WTS (10/25/2027) TO PUR COM | 10-Q: FY2025 Q3 Revenue: USD 2.855 K